Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH has issued a Tender notice for the procurement of a Nanobody against Nprc for Growth Disorder in the USA. This Tender notice was published on 19 Aug 2026 and is scheduled to close on 28 Aug 2026, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 147498268, while the tender notice number is 75N98026Q01031 and Registering on the platform.
Procurement Summary
Country: USA
Summary: Nanobody against Nprc for Growth Disorder
Deadline: 28 Aug 2026
Posting Date: 19 Aug 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 147498268
Document Ref. No.: 75N98026Q01031
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details Tender Details See attached Word document. Documents
Project Title: Nanobody against NPR-C for growth disorder
1. Project Overview
1.1 Background
We sought to develop nanobodies (VHH) against human NPR-C with high affinity and specificity for future clinical use. These nanobodies could potentially be further developed into therapeutics for treatment of growth disorders such as achondroplasia.
1.2 Main Objectives
- generation of antigens needed for immunization
- immunization of Alpaca/Ilama with target antigens generated
- generation of immunized phage/yeast library and in vitro screening using the library
- alternatively, single B-cell screening and sequencing instead of phage/yeast library generation/screening.
- downstream functional confirmation of VHH nanobodies binding to target antigens
- generation of final VHH-Fc candidates for further validation
1.3 Intended Use of Antibodies
Research (Western blot, immunohistochemistry, ELISA)
Animal testing (subcutaneous injection in mice)
Therapeutic lead generation (in combination with other antibody domains, Fc, etc)
2. Target / Antigen Information
Field
Detail
Target name/ID
Human NPR-C (P17342 · ANPRC_HUMAN)
Species reactivity required
Human / Mouse / Rat / Cross-reactive
Target type
secreted / extracellular domain
Antigens to be provided (amount needed: 0.5-2mg)
Human NPR-C, Fc tag (immunization)
Human NPR-C, His tag (immunization)
Biotinylated human NPR-C, His tag (panning)
Mouse NPR-C, His tag (immunization)
Human NPR2, mFc tag (counter screening)
Human IgG1 Fc Protein, His-Avi Tag (counter screening)
Human CNP (blocking screening)
Known structural considerations
Avoid cross-reactivity with Alpaca/Llama NPR-C and NPR-B
3. Scope of Work
Development Platform
Track 1: Phage display or Yeast display using immunized library
Track 2: Single B-cell cloning
3.2.1 Workstream Breakd...
Notice ID: 75n98026q01031
Department/Ind. Agency: health and human services, department of
Original Set Aside: total small business set-aside (far 19.5)
Sub-tier: national institutes of health
Office: national institutes of health olao
Product Service Code: r499 - support- professional: other
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Inactive Dates: aug 29, 2026
Inactive Policy: manual
Procurement Documents for USA
Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google